Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- Registration Number
- NCT06463028
- Lead Sponsor
- Faeth Therapeutics
- Brief Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Detailed Description
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer who have failed prior systemic therapies, including a platinum-based therapy and an immune checkpoint inhibitor, either separately or together.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 40
- Histologically confirmed diagnosis of endometrioid endometrial carcinoma.
- Documented evidence of advanced or recurrent endometrial cancer that is not amenable to surgery/radiation for curative intent.
- Participant has received at least 1 but not more than 3 prior systemic therapies. Prior therapy must include platinum-based chemotherapy and a checkpoint inhibitor, either separately or in combination.
- PI3K/AKT/mTOR pathway gene alteration identified.
- At least 1 measurable target lesion according to RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at Screening.
- Non-pregnant, non-lactating females who are postmenopausal, surgically sterile or who agree to use effective contraceptive methods..
- Participants with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study
- Active malignancy (except for endometrial cancer, definitively treated in-situ carcinomas [e.g., breast, cervix, bladder], or basal or squamous cell carcinoma of the skin) within the past 24 months prior to treatment. Fully resected localized malignancies are eligible.
- Gastrointestinal malabsorption, gastrointestinal anastomosis, bowel obstruction, or any other condition that might affect the absorption of study treatment.
- Clinically significant hemoptysis or tumor bleeding.
- Significant cardiovascular impairment.
- Active, uncontrolled (requiring systemic antimicrobial therapy) infection.
- Concurrent participation in another therapeutic clinical trial.
- Prior radiation therapy within 21 days prior to start of study treatment.
- Strong CYP3A4 inhibitors, strong CYP1A2 inhibitors or CYP1A2 inducers, or clinically significant CYP3A4 inducers within 7 days before the first dose of study intervention, or participants who require treatment with strong CYP3A4 inhibitors or inducers during the study.
- Participants who require PPIs or chronic use of antacids, histamine H2 receptor blockers, or other treatments to raise gastric pH.
- Prolongation of QTc interval to >480 ms.
- HbA1c ≥ 8.0%, fasting serum glucose > 160 mg/dL, fasting triglycerides > 300 mg/dL or receiving treatment with insulin.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description sapanisertib and serabelisib (PIKTOR) with paclitaxel Sapanisertib Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously. sapanisertib and serabelisib (PIKTOR) with paclitaxel Serabelisib Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously. sapanisertib and serabelisib (PIKTOR) with paclitaxel Paclitaxel Subjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously.
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) Up to 2 years Defined as the proportion of participants with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR).
- Secondary Outcome Measures
Name Time Method Progression free survival (PFS) Up to 5 years. Defined as the time from first dose until the date of disease progression or death.
Progression free survival (PFS) at 6 months Up to 5 years. Defined as PFS rate at 6 months.
Overall survival (OS) Up to 5 years. Defined as the time from first dose to death.
Clinical benefit rate (CBR) Up to 5 years. Defined as the percentage of participants who achieve complete response (CR), partial response (PR), or have stable disease (SD) of at least 16 or 24 weeks.
Duration of response (DoR) Up to 5 years. Defined for participants with confirmed CR or PR as the time from response until date of documented disease progression or death.
Safety and tolerability of drugs by assessment of adverse events (AEs) / serious adverse events (SAEs) Up to 2 years. Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V5.0).
Trial Locations
- Locations (10)
UC San Diego Moores Cancer Center
🇺🇸La Jolla, California, United States
Mount Sinai Comprehensive Cancer Center
🇺🇸Miami Beach, Florida, United States
Florida Cancer Specialists, North
🇺🇸Saint Petersburg, Florida, United States
Florida Cancer Specialists, East
🇺🇸West Palm Beach, Florida, United States
Minnesota Oncology Hematology, P.A.
🇺🇸Maple Grove, Minnesota, United States
Oncology Associates of Oregon, P.C.
🇺🇸Eugene, Oregon, United States
Northwest Cancer Specialists, P.C.
🇺🇸Portland, Oregon, United States
Alliance Cancer Specialists, PC
🇺🇸Doylestown, Pennsylvania, United States
Women's Cancer Care Associates, LLC
🇺🇸Albany, New York, United States
Avera Cancer Institute
🇺🇸Sioux Falls, South Dakota, United States